STOCK TITAN

Nurix Therapeutics (NRIX) DEF 14A Filings

NRIX NASDAQ

Here are the DEF 14A proxy statements from Nurix Therapeutics, Inc. (NRIX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRIX filings page.

Rhea-AI Summary

Nurix Therapeutics has issued its 2026 proxy for a virtual annual meeting on May 15, where stockholders will vote on electing three Class III directors, ratifying PricewaterhouseCoopers as auditor, and a non-binding say-on-pay proposal. The CEO’s letter highlights strong 2025 pipeline progress, led by BTK degrader bexobrutideg, which showed an 83.0% objective response rate and 22.1-month median progression-free survival in heavily pretreated CLL, and a 75.0% response rate in Waldenström macroglobulinemia. Nurix ended fiscal 2025 with $592.9 million in cash, cash equivalents and marketable securities and completed a $250.0 million underwritten offering, while recognizing $84.0 million in collaboration revenue and remaining eligible for up to $6.1 billion in future milestones and royalties.